[Skip to Content]

Upstate Active Clinical Trials

Study Title:

ACNS1821 - A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

What is the purpose of the study? (in Layman's terms, please describe the study)

A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Upstate Institutional Review Board (IRB) Number:

1921131

Study/Protocol ID:

ACNS1821

Study Phase:

I/II

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who is eligible?

≥ 12 months and ≤ 21 years of age

What is involved if I participate?

  • How long is the study?
    N/A
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    N/A

Where will the study take place?

Upstate Pediatric Cancer Center

Other Information:

N/A

Who can I contact for more information?

Name: Suzanne M Majewski
Phone: 315-464-7232
Email: [email protected]

Return to Previous Page || Search Again

Top